Product Profiles: Disease Modification in Rheumatoid Arthritis - Game-changing therapy close to market
- Published: January 2012
TechNavio’s analysts forecast the Global Rheumatoid Arthritis Drugs market to grow at a CAGR of 12.1 percent over the period 2011–2015. One of the key factors contributing to this market growth is the high incidence and prevalence rate of patients suffering from rheumatoid arthritis. The Global Rheumatoid Arthritis Drugs market has also been witnessing the trend of preference for combination therapies for treatment of rheumatoid arthritis. However, patent expiry of blockbuster drugs could pose a challenge to the growth of this market.
TechNavio’s report, the Global Rheumatoid Arthritis Drugs Market 2011–2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Rheumatoid Arthritis Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include Abbott Laboratories, Johnson & Johnson, Pfizer Inc., Amgen Inc., and Roche Pharmaceuticals Inc.
Key questions answered in this report:
What will the market size be in 2015 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors? SHOW LESS READ MORE >
01. Executive Summary
03. Market Coverage
04. Market Landscape
05. Geographical Segmentation
06. Key Leading Countries
07. Rate of Incidence and Prevalence
08. Vendor Landscape
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
15.1 Abbott Laboratories
15.2 Johnson & Johnson
15.3 Pfizer Inc.
15.4 Amgen Inc.
15.5 Roche Pharmaceuticals Inc.
16. Other Reports in this Series
List of Exhibits:
Exhibit 1: Global Rheumatoid Arthritis Drugs Market 2011-2015 (US$ billion)
Exhibit 2: Global Rheumatoid Arthritis Drugs Market by Geographical Segmentation 2011
Exhibit 3: Global Rheumatoid Arthritis Drugs Market by Vendor Segmentation 2011
TechNavio Announces the Publication of its Report – Global Rheumatoid Arthritis Drugs Market 2011–2015
TechNavio today launched its report Global Rheumatoid Arthritis (RA) Drugs Market 2011–2015 based on an in-depth study covering the Americas, and the EMEA and APAC regions. The report aims to aid decision makers’ understanding of the significant trends impacting this market.
Commenting on the report, an analyst from TechNavio’s Healthcare team said, “Though the Global RA Drugs market has matured, most of the innovations by the biopharmaceutical and pharmaceutical vendors are either still in the development stages or awaiting approval. For instance, Denosumab from Amgen is in the second phase of development and it is expected to enter the RA Drugs market soon. Biologic drugs create better opportunities for vendors to modulate disease progression and alleviate the chronic cycle of inflammation and pathology. Both leading vendors and small and domestic vendors are strengthening their position in the market by introducing new and effective biologic drugs. Therefore, the introduction of new products that are at present in the development stages will have a major impact on the market.”
According to the report, a major trend in the Global RA Drugs market at present is the use of a combination of therapies to treat patients with RA. Many rheumatologists agree that biologic drugs are most effective when combined with surgery and physical therapy. Furthermore, DMARDs are also combined with biologic agents, which help to reduce the pain in the joints and minimize the damage and inflammation of the joints caused by the disease.
Further, the report also discusses that the availability of alternative treatments limits the usage of RA drugs, posing a challenge to the Global RA Drugs market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
- Abbott Laboratories
- Johnson & Johnson
- Pfizer Inc.
- Amgen Inc.
- Roche Pharmaceuticals Inc.